AMES, Iowa, Feb. 22, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics (Nasdaq:NLNK) announced today that Dr. Charles Link, Chairman and CEO, will participate in a panel discussion at the 2012 RBC Capital Markets Global Healthcare Conference on Wednesday, February 29, 2012 at 11 a.m. Eastern time in New York, NY. The panel will be moderated by Dr. Jason Kantor and will include panelists from two other companies, Oncothyreon, Inc. and Vical, Inc. in addition to NewLink. The panel will focus on late stage Phase 3 clinical programs and is titled “The Future of Immunotherapy; Key Phase III Trials to Watch.”
